A pathway-driven predictive model of tramadol pharmacogenetics

Frank R. Wendt, Nicole M.M. Novroski, Anna Liina Rahikainen, Antti Sajantila, Bruce Budowle

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Predicting metabolizer phenotype (MP) is typically performed using data from a single gene. Cytochrome p450 family 2 subfamily D polypeptide 6 (CYP2D6) is considered the primary gene for predicting MP in reference to approximately 30% of marketed drugs and endogenous toxins. CYP2D6 predictions have proven clinically effective but also have well-documented inaccuracies due to relatively high genotype–phenotype discordance in certain populations. Herein, a pathway-driven predictive model employs genetic data from uridine diphosphate glucuronosyltransferase, family 1, polypeptide B7 (UGT2B7), adenosine triphosphate (ATP)-binding cassette, subfamily B, number 1 (ABCB1), opioid receptor mu 1 (OPRM1), and catechol-O-methyltransferase (COMT) to predict the tramadol to primary metabolite ratio (T:M1) and the resulting toxicologically inferred MP (t-MP). These data were then combined with CYP2D6 data to evaluate performance of a fully combinatorial model relative to CYP2D6 alone. These data identify UGT2B7 as a potentially significant explanatory marker for T:M1 variability in a population of tramadol-exposed individuals of Finnish ancestry. Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone.

Original languageEnglish
Pages (from-to)1143-1156
Number of pages14
JournalEuropean Journal of Human Genetics
Volume27
Issue number7
DOIs
StatePublished - 1 Jul 2019

Fingerprint Dive into the research topics of 'A pathway-driven predictive model of tramadol pharmacogenetics'. Together they form a unique fingerprint.

Cite this